What the Latest IVD and Evidence Synthesis Updates Mean for Manufacturers

By: Sarah VanVickle Chaves, Director of IVD and Scientific Writing Services, Ph.D. Molecular and Cellular Biology

FDA and Cochrane updates published in November 2026 

13 November 2026 

A few developments landed this week that anyone working in IVD or evidence synthesis will want on their radar: an FDA proposal affecting oncology immunohistochemistry test systems, final FDA guidance on validating certain emerging-pathogen diagnostics, and new Cochrane guidance on keeping evidence current and planning syntheses prospectively. Each one tackles a different piece of the evidence puzzle, from the questions a performance study has to answer to how a review stays up to date.  

Before digging in, it’s worth asking how much weight each one really carries. A proposed US classification change, a methodological recommendation, and final nonbinding guidance are very different things. If you’re working on performance evaluation reports (PERs), clinical evaluation reports (CERs), or state-of-the-art (SOTA) reviews, think of these updates as useful prompts for your evidence planning. Whether they matter for you depends on your product, your jurisdiction, and the claim you’re assessing. And the workflow ideas below are practical suggestions, not additional regulatory requirements. 

FDA wants to rethink how some oncology IHC tests get to market 

On 12 November 2026, FDA published a proposed order that would move specified immunohistochemistry (IHC) test systems used with approved oncology therapeutic products out of Class III, where premarket approval is required, and into Class II with special controls and premarket notification. The proposal would create a new category under 21 CFR 864.1895. To be clear, this isn’t a final reclassification yet.  

The proposed special controls cover a lot of ground: clinical specimens that represent the intended population, validation near clinical cutoffs, reproducibility across readers and sites, robustness, and specimen stability. While the proposal is still under consideration, that gives manufacturers a concrete framework to measure their own evidence against.  

Tie the treatment claim back to the evidence 

If you make IHC tests, a good first exercise is to line up each proposed claim next to the data behind it. Saying an assay detects protein expression is one thing. Saying it informs whether a patient should get an oncology therapy is another, and each needs its own explanation of clinical relevance. Your review should make that difference easy to see. 

Picture a hypothetical assay with strong overall agreement but not much data on specimens sitting close to its decision threshold. The aggregate numbers look good, but the treatment-selection question could still be wide open. An evidence map can show you which study speaks to that uncertainty, which specimens it includes, and what its results actually support. Think of this as one way to spot a gap, not a study design everyone needs to follow. 

What this means for manufacturers and regulatory writers 

Manufacturers can treat the proposal as a chance to run an early gap assessment without changing their current regulatory strategy. Regulatory writers can help by keeping biological association, analytical performance, and evidence for the proposed clinical role clearly separate. When summarizing studies, they should also hold on to the details that matter: the specimen, scoring method, platform, and reader conditions. 

Keep in mind that the proposal is about a defined US category. It doesn’t change EU IVDR classification, so don’t describe its proposed controls in a PER as newly binding EU requirements. For multinational programmes, record the US proposal separately from the applicable EU obligations, and explain any evidence rationale the two share. 

US Food and Drug Administration. Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product. Proposed amendment; proposed order; request for comments. Published 12 November 2026. 91 FR 72825–72837. FR document 2026-23005. Docket FDA-2026-N-12508. 

FDA finalizes its validation guidance for emerging pathogen diagnostics 

On 10 November 2026, FDA issued its final guidance, Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency. It contains nonbinding recommendations for that specific emergency context, including evidence submitted through pre-EUA and EUA requests or relevant enforcement-discretion policies.  

FDA’s preference is natural clinical specimens. Early in an outbreak those may not be available, so alternative materials can support initial validation, but relying on contrived specimens would likely come with a condition requiring later clinical evaluation using natural patient specimens. The guidance also covers intended-use populations and settings, specimen differences, and performance analysis, including positive and negative percent agreement with confidence intervals.  

Turn the evidence limitations into a working plan 

If you’re developing an emergency diagnostic, a practical move is to describe what your initial evidence can establish and what it leaves unresolved. A follow-up plan is more useful when it names the question, a realistic source of specimens, and the point where the team will reassess its conclusion. 

Say a hypothetical developer uses contrived samples. They could keep a record of what those samples contributed to the initial evaluation, which clinical conditions they don’t represent, and what activity is planned to close those gaps. That way study teams, regulatory affairs, and scientific writers all work from the same interpretation when they prepare later reports. 

Be clear about jurisdiction and context 

EU evidence teams can use the document to pressure-test specimen representativeness and uncertainty in their own plans. What they shouldn’t do is read FDA’s emergency flexibility as permission to defer evidence under IVDR. Any EU conclusion needs its own justification against the applicable requirements and the device’s intended purpose. 

US Food and Drug Administration. Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency. Final guidance for industry and FDA staff. Issued 10 November 2026. Document GUI00007020. Docket FDA-2024-D-2707. 

Cochrane has new guidance on keeping evidence current and planning ahead 

On 10 November 2026, Cochrane announced a new chapter on living systematic reviews, along with substantial revisions to its prospective meta-analysis guidance. Handbook version 6.5.1 now includes Chapter 21, Living systematic reviews, by Hodder and colleagues, and Chapter 22, Prospective, collaborative approaches to meta-analysis, by Seidler and colleagues. Both are methodological recommendations.  

Chapter 21 covers when a living approach makes sense, how often to search for and fold in new evidence, and how to communicate between updates. Chapter 22 looks at prospective approaches, where studies and methods are identified before anyone knows the results. Working together this way supports more consistent data and lowers the potential for bias.  

Decide what an update will actually change 

For CER, PER, and SOTA teams, one practical takeaway is to separate a search update from a revision of the evidence conclusion. Pulling in new records is one job. Deciding whether they change the comparator, clinical benchmark, risk assessment, or performance conclusion takes appraisal and interpretation. 

Your review protocol can spell that out. Say a team is watching a fast-moving diagnostic field. They could document the search interval, who does the screening, the questions used to judge relevance, and what would trigger a revised synthesis. It also helps to keep a dated decision on file when no revision is needed, so the next reviewer can see what was assessed. 

Pick a review model you can sustain 

Cochrane generally recommends searching at least every three months for living systematic reviews, with the interval reflecting how fast the research is moving. That’s not a universal IVDR or MDR search-frequency rule. And the Handbook is about intervention reviews, so diagnostic-performance reviews need methods that suit their own questions and data.  

So manufacturers should decide whether a living approach is useful and feasible for a particular evidence question. For regulatory professionals, the nearer-term opportunity is tightening up the protocol and the update record. A scheduled search should lead to a documented assessment of what it means, and you need enough expertise and resources to keep the process going. 

Hodder RK, McDonald S, Synnot A, Millard T, Thomas J, Cumpston M, Turner T. Chapter 21: Living systematic reviews. In: Higgins JP et al., editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5.1. Cochrane; 2026. 

Seidler AL, Godolphin PJ, Hunter KE, et al., on behalf of the Cochrane Prospective Meta-Analysis Methods Group. Chapter 22: Prospective, collaborative approaches to meta-analysis. Updated November 2026. In: Higgins JP et al., editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5.1. Cochrane; 2026. 

Turn the updates into product-specific decisions 

A good next step is a focused impact assessment for a single product or review programme. Regulatory affairs can work out which document applies and what its status is. Clinical and technical reviewers can pin down the evidence question it raises. Scientific writers can then explain the resulting conclusion, and its limits, in the relevant report. 

For an oncology IHC portfolio, that might mean checking cutoff and reader evidence against the FDA proposal. For a literature programme, it might mean deciding when surveillance findings should trigger a synthesis update. For an emergency diagnostic, it might mean spelling out how the initial evidence will be supplemented. Whatever the case, finish each assessment with a reasoned decision and an owner for any further work. 

References 

US Food and Drug Administration. Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product. Proposed amendment; proposed order; request for comments. Published 12 November 2026. 91 FR 72825–72837. FR document 2026-23005. Docket FDA-2026-N-12508. 

US Food and Drug Administration. Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency. Final guidance for industry and FDA staff. Issued 10 November 2026. Document GUI00007020. Docket FDA-2024-D-2707. 

Hodder RK, McDonald S, Synnot A, Millard T, Thomas J, Cumpston M, Turner T. Chapter 21: Living systematic reviews. In: Higgins JP et al., editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5.1. Cochrane; 2026. 

Seidler AL, Godolphin PJ, Hunter KE, et al., on behalf of the Cochrane Prospective Meta-Analysis Methods Group. Chapter 22: Prospective, collaborative approaches to meta-analysis. Updated November 2026. In: Higgins JP et al., editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5.1. Cochrane; 2026. 

TALK TO AN EXPERT

Whether you’re navigating a complex regulatory submission, preparing for an audit, or simply exploring outsourced support — our team is here to help.

Criterion Edge specializes in high-quality, compliant medical writing services for the life sciences industry. Use the form to tell us a bit about your needs — one of our experts will follow up within one business day.

Need a faster response? Use the chat icon in the lower-right corner to speak with us immediately during business hours.

  • No obligation — just an open conversation
  • Expert guidance from PhD-level writers
  • Trusted by leading MedTech & Pharma companies
  • Fast turnaround for time-sensitive projects
  • Clear quotes and scoping available

How Can We Help?

TALK TO AN EXPERT

Whether you’re navigating a complex regulatory submission, preparing for an audit, or simply exploring outsourced support — our team is here to help.

Criterion Edge specializes in high-quality, compliant medical writing services for the life sciences industry. Use the form to tell us a bit about your needs — one of our experts will follow up within one business day.

Need a faster response? Use the chat icon in the lower-right corner to speak with us immediately during business hours.

  • No obligation — just an open conversation
  • Expert guidance from PhD-level writers
  • Trusted by leading MedTech & Pharma companies
  • Fast turnaround for time-sensitive projects
  • Clear quotes and scoping available

How Can We Help?

Criterion Edge
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Read more about our privacy policy here.